Henlius Doses First Patient In China For Ophthalmic Bevacizumab
Follows US FDA Approving Henlius’ Investigational New Drug Application
Chinese firms Shanghai Henlius Biotech and Essex Bio-Technology have announced a key milestone in their Chinese Phase I clinical study for the HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration.
